The in-vitro anticoagulant effect of rivaroxaban in neonates

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 3, 2014, Pages 237-240

  Attard, Chantal ^a   Monagle, Paul ^a,b   Kubitza, Dagmar ^c   Ignjatovic, Vera ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BAYER PHARMA AG   (Germany)

Author keywords

Anticoagulant; Developmental haemostasis; Direct Factor Xa inhibitor; Neonate; Rivaroxaban; Vitamin K antagonist

Indexed keywords

RIVAROXABAN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; GROUPS BY AGE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; AGE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; FEMALE; MALE;

AGE FACTORS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MORPHOLINES; THIOPHENES;

EID: 84897575011     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000033     Document Type: Article

References (24)

1. Monagle P, Chalmers E, Chan A, deVeber G, KirkhamF, Massicotte P, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:887S-968S.
2. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:645S-687S.
3. Young G. New anticoagulants in children: A review of recent studies and a look to the future. Thromb Res 2011; 127:70-74
4. Barnes C, Newall F, Ignjatovic V, Wong P, Cameron F, Jones G, et al. Reduced bone density in children on long-Term warfarin. Pediatr Res 2005; 57:578-581
5. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Thromb Res 2003; 109:101-108
6. Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, et al. Agerelated differences in heparin response. Thromb Res 2006; 118:741-745
7. Ignjatovic V, Summerhayes R, Yip YY, Monagle P. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults. Thromb Res 2008; 122:709-714
8. Ignjatovic V, Summerhayes R, Newall F, Monagle P. The in vitro response to low-molecular-weight heparin is not age-dependent in children. Thromb Haemost 2009; 103:855-856
9. Streif W, Ageno W. Direct thrombin and Factor Xa inhibitors in children: A quest for new anticoagulants for children. Wien Med Wochenschr 2011; 161:73-79
10. International Conference on Harmonisation; guidance on E11 clinical investigation of medicinal products in the pediatric population; availability. Fed Regist 2001; 65:78493-78494. Notice. http:// www.emea.europa.eu/pdfs/human/ ich/271199en.pdf. [Accessed 12 September 2011].
11. Attard C, Monagle P, Kubitza D, Ignjatovic V. The in vitro anticoagulant effect of rivaroxaban in children. Thromb Res 2012; 130:804-807
12. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006; 114:2374-2381
13. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891
14. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009; 374:29-38
15. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19
16. The EINSTEIN authors. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-2510
17. Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: The functional role of alpha-2-macroglobulin and influence of developmental haemostasis. Br J Haematol 2007; 138:366-368
18. Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost 2010; 6:1290-1294
19. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95:362-372
20. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten- Linder M, et al. Effects of the oral, direct Factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2010; 9:133-139
21. Lau A, Berry LR, Mitchell LG, Chan AK. Effect of substrate and fibrin polymerization inhibitor on determination of plasma thrombin generation in vitro. Thromb Res 2007; 119:667-677
22. Chandler WL, Patel MA, Gravelle L, Soltow LO, Lewis K, Bishop PD, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12:101-108
23. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: Results of a multicenter field trial. Clin Appl Thromb Hemost 2012; 18:150-158
24. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, et al. Evaluation of the antifactor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107:379-387.